R

Replimune Group
D

REPL

13.260
USD
-1.62
(-10.89%)
Pre Open
Volume
680
EPS
-3
Div Yield
-
P/E
-4
Market Cap
907,215,307
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    AAPL
    -3.130
    (-1.37%)
    225.060 USD
    AMZN
    AMZN
    -8.930
    (-4.22%)
    202.550 USD
    C
    CLOV
    -0.03000
    (-0.97%)
    3.05000 USD
    CRM
    CRM
    -6.22
    (-1.88%)
    325.35 USD
    DIS
    DIS
    5.915
    (5.42%)
    115.065 USD
    GOOGL
    GOOGL
    -3.110
    (-1.77%)
    172.490 USD
    MSFT
    MSFT
    -11.75
    (-2.75%)
    415.00 USD
    NFLX
    NFLX
    -13.37
    (-1.60%)
    823.95 USD
    TSLA
    TSLA
    9.69
    (3.11%)
    320.87 USD
    More
News

Title: Replimune Group

Sector: Healthcare
Industry: Biotechnology
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.